You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Harvard Business School

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 8,343,955

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,343,955
Title:Benzoxazepin PI3K inhibitor compounds and methods of use
Abstract: Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z.sup.1 is CR.sup.1 or N; Z.sup.2 is CR.sup.2 or N; Z.sup.3 is CR.sup.3 or N; Z.sup.4 is CR.sup.4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. ##STR00001##
Inventor(s): Blaquiere; Nicole (South San Francisco, CA), Do; Steven (South San Francisco, CA), Dudley; Danette (South San Francisco, CA), Folkes; Adrian (Basel, CH), Heald; Robert (Harlow, GB), Heffron; Timothy (South San Francisco, CA), Jones; Mark (Harlow, GB), Kolesnikov; Aleksandr (South San Francisco, CA), Ndubaku; Chudi (South San Francisco, CA), Olivero; Alan G. (South San Francisco, CA), Price; Stephen (Harlow, GB), Staben; Steven (South San Francisco, CA), Wang; Lan (South San Francisco, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:13/477,587
Patent Claims:see list of patent claims

Details for Patent 8,343,955

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Genentech, Inc. (South San Francisco, CA) 2039-02-26 RX Orphan search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08   Start Trial Genentech, Inc. (South San Francisco, CA) 2039-02-26 RX search
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Genentech, Inc. (South San Francisco, CA) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.